Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide An Analysis From the NRG Oncology/RTOG 0424 Trial Article

Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2018). Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide An Analysis From the NRG Oncology/RTOG 0424 Trial . JAMA ONCOLOGY, 4(10), 1405-1409. 10.1001/jamaoncol.2018.1977

Open Access International Collaboration

cited authors

  • Bell, Erica H; Zhang, Peixin; Fisher, Barbara J; Macdonald, David R; McElroy, Joseph P; Lesser, Glenn J; Fleming, Jessica; Chakraborty, Arup R; Liu, Ziyan; Becker, Aline P; Fabian, Denise; Aldape, Kenneth D; Ashby, Lynn S; Werner-Wasik, Maria; Walker, Eleanor M; Bahary, Jean-Paul; Kwok, Young; Yu, H Michael; Laack, Nadia N; Schultz, Christopher J; Gray, Heidi J; Robins, H Ian; Mehta, Minesh P; Chakravarti, Arnab

sustainable development goals

authors

publication date

  • October 1, 2018

published in

keywords

  • GENE
  • GLIOBLASTOMA
  • LOW-GRADE GLIOMA
  • Life Sciences & Biomedicine
  • Oncology
  • Science & Technology

Digital Object Identifier (DOI)

publisher

  • AMER MEDICAL ASSOC

start page

  • 1405

end page

  • 1409

volume

  • 4

issue

  • 10